WO2001079445A2 - Pluripotent cells comprising allogenic nucleus and mitochondria - Google Patents
Pluripotent cells comprising allogenic nucleus and mitochondria Download PDFInfo
- Publication number
- WO2001079445A2 WO2001079445A2 PCT/US2001/012265 US0112265W WO0179445A2 WO 2001079445 A2 WO2001079445 A2 WO 2001079445A2 US 0112265 W US0112265 W US 0112265W WO 0179445 A2 WO0179445 A2 WO 0179445A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- allochimeric
- human
- chimeric
- nucleus
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 248
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 31
- 230000004069 differentiation Effects 0.000 claims abstract description 15
- 210000000287 oocyte Anatomy 0.000 claims description 67
- 241000894007 species Species 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 210000003754 fetus Anatomy 0.000 claims description 13
- 210000005260 human cell Anatomy 0.000 claims description 10
- 238000003306 harvesting Methods 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 2
- 108091029865 Exogenous DNA Proteins 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 abstract description 12
- 230000018109 developmental process Effects 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 210000004940 nucleus Anatomy 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 18
- 241000283690 Bos taurus Species 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 16
- 210000000056 organ Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 230000035800 maturation Effects 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 210000004681 ovum Anatomy 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 230000007159 enucleation Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 210000004508 polar body Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002459 blastocyst Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960000182 blood factors Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000001459 mortal effect Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001779 taste bud Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101500028876 Bos taurus Neurotensin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 108010024515 Eye Proteins Proteins 0.000 description 1
- 102000015764 Eye Proteins Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007908 penetration of oocytes Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 210000003537 structural cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/166—Animal cells resulting from interspecies fusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the field of the invention is the manipulation of cells to provide non-human oocytes for nucler transfer procedures wherein such nuclear transfer units possess allogenic nucleus and mitochondria from two different cellular sources of the same species.
- Embryonic stem (“ES”) cells offer opportunities to produce differentiated cells, organs and complete individuals upon demand, so that one may clone a particular genotype.
- livestock animals e.g.
- modified oocytes and ES cells capable of being expanded in culture and differentiating to different cell types, engineered ES cells, differentiated cells derived therefrom, organs or portions thereof and organisms derived thereby.
- the methods comprise employing an allogenic egg cell, where allogenic intends the ultimate species. intended for the cell, which is enucleated and into which is introduced a xenogenic nucleus, to provide a chimeric cell having cytoplasm and mitochondria from one species and a nucleus from a different species.
- the ES cells After expansion of the chimeric cell to provide a nuclear transfer (NT) unit from which ES cells may be derived, the ES cells may be used for further expansion and scientific investigation, or the NT unit may be transferred into an allogenic, syngenic or other compatible xenogenic host uterus (based on the original oocyte) for pregnancy and birth.
- Oocytes from this Fl animal may then be harvested, enucleated and an allogenic nucleus introduced to provide an egg cell which can provide cells having proteins of a single species, be immunologically competent and which can be accepted with a reduced risk of rejection when implanted in an allogenic host.
- these cells and their progeny will be referred to as "allochimeric.”
- Allochimeric cells comprising mitochondria from a first individual of a first species and a nucleus from a second individual from the same first species.
- pluripotent cells capable of development into a fetus or into a plurality of different cell types will be produced comprising mitochondria from an allogenic species, where allogenic species intends the species of interest, and a xenogenic nucleus, where xenogenic intends the species in which the cells will be implanted or a different species compatible with implantation of the cells and the cells differentiating into a fetus.
- the developed or matured fetus will then be used for harvesting oocytes, enucleating the oocytes, and introducing a nucleus from the same species as the mitochondria.
- the resulting allochimeric cells may be used in vitro and in vivo for studying differentiation, for producing cells along different differentiation paths, e.g. ectoderm, endoderm or mesoderm, and cells within these classifications, such as neuronal cells, neurons, astrocytes, glial cells, ganglions, etc., hematopoietic cells, e.g. lymphocytes, macrophages, NK cells, erythrocytes, megakaryocytes, etc., fibroblasts, myoblasts, etc.
- the subject methodology involves the following primary stages: •
- Egg cells may be harvested from any convenient host of interest, for which one wishes mitochondria from a species of interest.
- any mammalian species of interest may serve as the source of the egg cells, particularly domestic animals, more particularly large domestic animals, exemplified by equine, bovine, ovine, porcine, feline, canine, lagomorpha, murine, etc., and primate, exemplified by human, monkey and ape.
- the oocytes may be harvested in any convenient way, depending upon whether there are sources of follicles from slaughtered animals or a surgical procedure is required.
- primate cells more particularly human cells, which may serve for production of differentiated cells.
- the cells may come from any member of the species, as the nucleus which will be subsequently employed will determine the species and the histocompatibility of the cells.
- the subject invention finds particular application with human cells, although there will be instances with other species where allochimeric cells can play a role, e.g. rare and valuable animals, animals for which in vitro fertilization is not reasonably feasible, and the like.
- the egg cells may be matured in vitro in accordance with known techniques, using appropriate maturation medium.
- Oocytes having polar bodies may be employed as the host cells. See, for example, Prather et al., Differentiation 48:1-8 (1991) and Seshagine et al., Biol. Reprod. 40:544-606 (1989))
- Enucleation is achieved in accordance with conventional ways, conveniently using a micropipette to remove polar bodies and surrounding cytoplasm. The oocytes are then screened to establish the successful enucleation.
- the somatic nuclei may be engineered by the introduction of genes important for mitochondrial function in the type of mitochondria present in the egg cell.
- the subject invention finds particular application in the introduction of human nuclear mitochondrial genes into animal, particularly bovine somatic cells to facilitate cellular function of an animal cell with human mitochondria.
- a wide variety of mammalian hosts may be employed as the source of the nuclei, where the issue will be primarily one of convenience. Besides the necessity for growing the chimeric NT unit to term, other considerations in the selection of the host source will be ease of harvesting the oocytes from the host, ease of manipulation and growth in culture, maturity of the technology, prior success rate in achieving progeny, ease of growth of the host, viability of the resulting chimeric oocytes, number of available oocytes, compatibility of the mitochondria with the host nucleus, as well as other practical considerations. While any mammalian host may be employed, of particular interest are domestic animals, more particularly, large domestic animals or primates other than humans.
- Exemplary mammals include ungulates, bovine and ovine, porcine, feline, equine, lagomorpha, murine, canine, etc.
- the isolated oocytes are matured in vitro and selected for the presence of polar bodies.
- the nuclei may come from any convenient source, germ or somatic cell, which can provide for the production of progeny. Therefore, the nuclei may come from fetal cells, neonate cells, mature cells, cells produced in a culture medium, or the like. Generally, neoplastic cell nuclei will not be used, but may have application depending on the nature of the neoplasm.
- the source may ne differentiated cells, which may be quiescent, G 0 or in an active state e.g. G, or G 2 .
- Cell types include one cell embryos (zygotes) or pronuclei, egg cells, blastomeres, epithelial cells, endothelial cells, muscle cells, keratinocytes, skin cells, alveolar cells, hepatocytes, renal cells, neuronal cells, hematopoietic cells, fibroblasts, endothelial cells, parenchymal cells, adipose cells, glial cells, follicular cells, etc., where the choice may be determined by a number of factors associated with the end purpose.
- Fusion and injection has been shown to be efficient, where the cell, which is the source of the nucleus, is placed into the perivitelline space of the enucleated oocyte and fused in a fusion chamber by means of an electrical pulse or using a fine glass needle, the donor nucleus or pronuclei from a fertilized oocyte can be isolated and delivered into the cytoplasm of the recipient egg.
- pronuclei may be from animals whose genomes have been modified to include nuclear mitochondrial genes of the same species as the recipient oocyte.
- Fusion can also be accomplished by using electrical pulses or by using various fusogenic reagents, e.g. Sendai virus. (See, for example, Graham, Wister Inot. Symp. Monogr. 9:19 (1969) and Collas and Barnes, Mol. Reprod. Dev. 38:264-267 (1994).)
- NT fused nuclear transfer
- a suitable medium e.g. CRIaa medium.
- activation will be effected shortly thereafter, usually within 24h, more usually 4 - 9h later.
- Activation may be accomplished by methods known for mammalian cells, such as culturing the NT unit at sub-physiological temperature, e.g. room temperature, penetration of oocytes by sperm, electrical and chemical shock, etc. See, for example, Susko-Parrish et al., U.S. Patent No. 5, 496, 720.
- Other methods include effecting simultaneous or sequential increasing of levels of divalent cations in the oocyte, e.g.
- kinase inhibitors e.g 6-diniemylaminopurine, staurosporine, roscovitine, butyrolactone, 2-aminopurine, and sphingosine, or introducing one or more phosphatases into the oocyte, e.g. phosphatase 2A or 2B.
- a technique of interest for activation is: activation of NT units within 18 to 30 hours after the start of culture in maturation medium.
- NT units are then removed from the culture media and placed in activation media (2mL TL Hepes with 2 mg of bovine serum albumin, 5mM of Ionomycin and 2mM of 6-DMAP for 4 minutes on a slide warmer. At the end of 4 minutes, the NT units are rinsed in TL Hepes and placed in culture media with 2mM of 6-DMAP at 38.5 ° and 5% CO 2 for 2 to 5 hours. At the end of this period, NT units are rinsed 4 times in TL Hepes and placed in culture. When the desired developmental stage is reached, ES cells will be derived or NT units will be transferred to recipient females.
- activation media 2mL TL Hepes with 2 mg of bovine serum albumin, 5mM of Ionomycin and 2mM of 6-DMAP for 4 minutes on a slide warmer. At the end of 4 minutes, the NT units are rinsed in TL Hepes and placed in culture media with 2mM of 6-DMAP at 38.5 ° and 5% CO 2 for 2
- the activated NT units of chimeric cells may then be cultured in a suitable in vitro or in vivo culture medium until the generation of ES cells and cell colonies developing embryos, such as blastocysts.
- Culture media suitable for culturing and maturation of ES cells and embryos are well known in the art.
- the chimeric cells may be treated as cells from the species of the nucleus, having the surface membrane proteins, cytoplasmic and nuclear proteins defined by the nuclear genes.
- Examples of known media include Ham's F-10 + 10% fetal calf serum (“FCS”), Tissue culture medium-199 (“TCM-199”) + 10% fetal calf serum, TyrodespAlbumin-Lactate-Pyruvate (“TALP”), Dulbecco's phosphate buffered saline (“PBS”), Eagle's and Whitten's media.
- FCS fetal calf serum
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TCM-199 Tissue culture medium-199
- TPM-199 10% fetal
- An exemplary media is TCM-199 with Earl salts, 10% fetal calf serum, 0.2mM Na pyruvate and 50 ⁇ g/ml gentamycin. These media may be used with cell lines to provide for conditioned media, using granulosa cells, oviduct cells, BRL cells, uterine cells and STO cells. Alternatively, the media described by Rosenkrans, jr., U.S. Patent No. 5, 096, 822 may be used.
- CR1 contains hemicalcium L-lactate in from about 1 to lOmM, usually 1 to 5mM, sodium chloride, potassium chloride, sodium bicarbonate, and a minor amount of fatty-acid free bovine serum albumin, and when essential and non-essential amino acids are added, the medium is referred to as CRlaa.
- An exemplary CR1 media comprises 114.7mM NaCl, 3.1 mM KC1, 26.2mM Na 2 CO 3 , 5mM hemicalcium L-lactate and 3mg/ml of fatty acid-free bovine serum albumin.
- the activated NT unit chimeric ES cells are placed in CRlaa media containing 1.9mM DMAP for about 4h, followed by a wash with HECM and then cultured in CRlaa containing BSA, at about 38.5°C, 5% CO 2 , for about 4 - 5 h.
- the cultured NT units are usually washed and placed in a suitable conditioned media for growth.
- An effective media is CRlaa media containing 10% FCS and 6 mg/ml BSA.
- Suitable feeder layers include fibroblasts and epithelial cells, particularly uterine epithelial cells, form sources such as ungulates, chicken, murine, STO, SI-m220 and BRL cells. Mouse embryonic fibroblasts have been found to be particularly useful. After sufficient time, which will vary with the species of the nucleus, chimeric ES cells are obtained which may now serve for msemination in an appropriate host.
- NT units are transferred to the uterus.
- the host is monitored to ensure that the NT units have been successfully implanted.
- the host may be restrained to prevent a spontaneous abortion.
- the delivery of the fetus or neonate may be spontaneous or induced abortion, natural delivery or cesarean section.
- the above stages will depend on the nature of the host. Normal maintenance of the host is employed to permit the neonate to grow as a healthy host. The harvesting of the oocytes may be performed as described above.
- the manner of enucleation and introduction of nuclei has already been discussed.
- the selection of the species for supplying the nucleus will depend on the purpose for which the cells are to be used.
- the cells may be used for cloning a particular species, particularly where oocytes are only difficultly grown in the species, such as humans or rare species, or as a source of differentiated cells, where the cells have both a nucleus and mitochondria from the same species.
- Other than human, other species which find application with the subject invention include the cloning of rare and endangered animals.
- the NT units are cultured on the feeder layer until the NT units reach a size suitable for the isolation of ES cells, generally requiring at least 4 cells, preferably at least 50 cells, and usually not exceeding 400 cells. Culturing will usually employ conditions of 38.5°C and 5% CO 2 , with the culture medium changed about every 1 - 5 days.
- the final stage involves mechanically removing the NT units from the culture, isolating cells from the inner portion of the NT unit, although cells from other portions of. the NT unit may find application, washing the cells from the NT unit and plating the cells on a feeder layer, e.g. irradiated fibroblast cells, from the same or different species from the nucleus.
- the cells are maintained on the feeder layer in a suitable growth media, e.g alpha- MEM supplemented with 10% FCS, O.lmM ⁇ -mercaptoethanol and L-glutamine.
- the growth media is conveniently changed about every 1 - 3 days.
- the individual cells are not well defined and the perimeter of the colony is refractive and smooth in appearance.
- the colony does not possess an epithelial-like appearance.
- the NT unit cells may use the NT unit cells to provide inner cell mass (ICM) cells of blastocysts.
- ICM inner cell mass
- the ICM cells can be grown in culture using feeder layers, e.g STO (mouse fibroblasts) with charcoal stripped serum
- the ES cells may be modified with DNA in accordance with conventional techniques. Bare DNA, recA coated DNA, viruses, plasmids, YACs, extrachromosomal DNA, chromosomal fragments, cDNA or other source of the desired gene, regulating sequence or the like may be introduced into the ES cells, using appropriate media, liposomes, transporting sequences, permeabilization, electrofusion or the like. See, for example, Schneike et al., Science 278:2130-3 (1997).
- the modifications can provide for the constitutive or inducible expression of a particular product, e.g. insulin angiogenesis factors, cytokines, e.g. interleukins, interferons and colony stimulating factors, blood factors, e.g. serum albumin, thrombin, fibrinogen, thrombopoietin, erythropoietin, tissue plasminogen activator,, etc. hormones, e.g. growth hormones, growth factors, e.g. epidermal growth factor, basic fibroblast growth factor, glial derived neurofrophic growth factor, etc., enzymes, enzyme inhibitors, e.g. ⁇ - antitrypsin, telomere associated proteins, e.g.
- a particular product e.g. insulin angiogenesis factors, cytokines, e.g. interleukins, interferons and colony stimulating factors
- blood factors e.g. serum albumin, thrombin, fibrinogen, thrombo
- Sir, telomerase, etc. neuronal proteins, e.g. neurotrophin-3,4/5, ciliary neurotrophic factor, etc., pancreatic proteins, basal proteins, taste bud proteins, eye proteins, hemoglobin, transcription factors, lipoproteins, immunoglobulins, surface membrane receptors, e.g. insulin receptor, oncogene repressors, L-dopamine, and angiogenesis inhibitors.
- neuronal proteins e.g. neurotrophin-3,4/5, ciliary neurotrophic factor, etc.
- pancreatic proteins basal proteins
- taste bud proteins eye proteins
- hemoglobin transcription factors
- lipoproteins e.g. insulin receptor
- immunoglobulins e.g. insulin receptor, oncogene repressors, L-dopamine, and angiogenesis inhibitors.
- surface membrane receptors e.g. insulin receptor, oncogene repressors, L-dopamine, and angiogenesis inhibitors.
- nuclei from subjects suffering from sickle cell anemia may be genetically modified to provide cells which provide a native hemoglobin; subjects suffering from hemophilia may have the mutant gene for the blood factor corrected, e.g. Factor NHIc or NHIvw, Christmas factor; subjects susceptible to diseases because of genetic factors, may have their nuclei modified to provide alleles less susceptible to such diseases, e.g. AIDS, juvenile onset diabetes, muscular dystrophy, Alzheimer's disease, Parkinson's disease, and so on.
- blood factor corrected e.g. Factor NHIc or NHIvw, Christmas factor
- subjects susceptible to diseases because of genetic factors may have their nuclei modified to provide alleles less susceptible to such diseases, e.g. AIDS, juvenile onset diabetes, muscular dystrophy, Alzheimer's disease, Parkinson's disease, and so on.
- genes which may be knocked out include oncogenes, histocompatibility proteins, blood type proteins and other genes whose dominant expression leads to pathology.
- Cells of interest include hematopoietic cells, neuronal cells, skeletal and cardiac muscle cells, skin cells, epithelial cells, endothelial cells, structural cells, osteoclasts and osteoblasts, follicle cells, eye cells, cells associated with sensing, such as taste buds inner ear cells, bone cells, renal cells, hepatocytes, pancreatic cells, e.g. ⁇ -islet cells, fibroblasts, and chondrocytes.
- the differentiated ES cells can find application in a wide variety of venues.
- the cells having allogenic mitochondria and nucleus provide cells which represent normal cells comprised of D ⁇ A from a single species.
- the proteins which are present in the cytoplasm are all of the same species, the interaction between the nucleus and the mitochondria, e.g. transport of proteins is natural, and the immunodominant sequences present on the surface of the cell will all be from the same species.
- ce ⁇ lular processes which depend on the interaction between the mitochondria and other infracellular compartments would also be natural.
- the ES cells and differentiated cells offer many opportunities for dissection of cellular processes, response to exogenous agents, e.g. genes, drugs, factors, etc., being used for screening the effect of these exogenous agents in the development of drugs, identifying specific alleles or mutations associates with the response to these outside agents, and investigating variations in transcription and expression in response to various agents.
- exogenous agents e.g. genes, drugs, factors, etc.
- the ES cells may be maintained in culture and expanded, one can repetitively produce the differentiated cells, where the cells will be based on the same genotype.
- the subject invention also offers the capability to use the nucleus from an individual for investigation and diagnosis. Thus, one may determine the susceptibility of a particular individual to outside agents, such as carcinogens, allergens, toxins, and mutagens where there is a complete cell of a single species having the native metabolism of such species. One can also investigate the cellular response to a particular regimen, e.g. drug regimen, to determine the effect on the normal cells of a particular patient.
- a particular regimen e.g. drug regimen
- ES cells which can be directed to produce various differentiated cells at different stages of differentiation, which can be subjected to the regimen and changes in the character of the cells determined.
- the subject invention allows for studying processes of mitochondria in conjunction with a particular nucleus.
- the subject methodology allows for cloning of such cells and seeing the effect of differentiation on the mitochondrial processes and the effect on growth patterns, phenotype, etc.
- the use of the native mitochondria avoids incompatibility when mating the resulting individual with other individuals of the same species.
- compositions which find use in the subject invention are oocytes comprising mitochondria from one species and a nucleus from a different species, isolated and in culture.
- the nucleus and mitochondria will be from species which substantially differ, generally being from a different genus and even different families.
- the nucleus will be chosen to provide for a useful source of the enucleated ovum, such as domestic animals (ungulates), e.g. bovine, ovine and porcine, and laboratory animals, e.g. murine.
- ova comprising mitochondria from one individual and a nucleus from a different individual of the same species, ES cells derived therefrom, cultures comprising such ES cells, differentiated cells derived therefrom, and cultures comprising such differentiated cells.
- compositions include allochimeric oocytes and ES cells in growth cultures for expansion of the cells.
- the compositions also include mixtures of allochimeric cells and differentiated cells of inner cell masses or concomitant growth or maintenance of ES cells and differentiated cells in culture media for cell differentiation.
- rIL-3 interleukin-3
- F final concentration 10%v/v
- FLS4.1 supernatant contains FLT3 ligand, steel factor and a new factor that supports growth of hematopoietic stem cells in 2 - 2.5 ml of culture medium [Iscove's Dulbecco's modified medium/50 ⁇ M 2-mercaptoethanol/2mM L-glutamine/gentamycin at 50 ⁇ g/ml /7.5% v/v FCS] at 37°C in a 7.5%CO 2 /92.5% air atmosphere. Every 5 - 7 days the cells are harvested and subcultured in new Costar 6-well plates containing mitomycin C-treated RP.0.10 stromal cells and freshly prepared cytokine-supplemented culture medium. (Palacios, et al., Proc. Natl.
- the ES cells are subject to an 8-day induction procedure which consists of 4 days of culture as aggregates without retinoic acid (RA) followed by 4 days of culture in the presence of RA.
- the medium is DMEM (high glucose with L-glutamine, without pyruvate; GIBCO 11965-043), 10% fetal bovine serum, 10% newborn calf serum and nucleosides stock.
- Other media may be employed for directing differentiation into other cell types, using factors which exist naturally and affect the differentiation in vivo, such as hematopoietic factors, e.g. G-CSF, M-CSF, GM-CSF, interleukins, interferons and other cytokines and growth factors.
- factors which exist naturally and affect the differentiation in vivo such as hematopoietic factors, e.g. G-CSF, M-CSF, GM-CSF, interleukins, interferons and other cytokines and growth factors.
- the enucleated oocytes may be stored frozen in a suitable medium for extended periods and then carefully thawed before use.
- the differentiated cells find use in therapy, where healthy cells can be introduced into the appropriate compartment to perform a desired function.
- myocytes may be used for grafting to myocardial tissue or other muscle tissue, where natural or genetically modified cells may provide an advantage, e.g. correction of a mutant protein, as in the case of muscular dystrophy. See, for example, U.S. Patent No. 5,602,301.
- Hematopoietic cells may be infused into a patient, such as lymphocytes, natural killer cells, megakaryocytes, eosinophils, basophils, mononuclear cells, or the precursors thereof, where the precursors may be dedicated to a specific cell type or may be multipotent and will differentiate to a number of different type cells, ⁇ -islet cells may be grafted onto the pancreas or provided in a protected container which may be innervated by a blood supply for treatment of diabetes.
- Neuronal cells may be introduced into the brain cavity to provide therapies for Parkinson's disease, Alzheimer disease, cerebral palsy, and the like, by providing a source of L-dopamine, NGE or other factors or other composition which can affect brain function.
- ES cells or their differentiated progeny include spinal cord injuries, multiple sclerosis, liver diseases, vascular diseases, bums cartilage replacement, heart diseases, kidney diseases, urinary tract diseases, prostate diseases, and diseases resulting from aging.
- the subject cells may be used to provide for enhanced supplies of particular factors, consfitutively or inducibly.
- Pruschy et al., Chem. Biol. 1: 163-72 (1997) provide modifications which allow for inducing production of a product by orally taking a pill, which activates a transcription factor.
- tissue plasminogen activator in the case of a heart attack, production of insulin for diabetics, activation of lymphocytes in the case of infection, through the introduction of non-human receptors such as theecdysone receptor, and the like.
- non-human receptors such as theecdysone receptor, and the like.
- Oocytes from human fetuses Fetal ovaries are obtained from human fetuses of 16- 20 weeks gestation following elective abortion. Ovarian tissues are minced into ⁇ lmm size and cultured in Waymouth media supplemented with 15%(v/v) fetal bovine serum, 0.03 IU/ml FSH and 35 ng/ml insulin. The tissue is cultured at 37°C in 5%CO 2 air for 5 - 25 days in Falcon dishes and 3 - 40 days in Costar Transwell-COL membranes prior to induction of final maturation in the presence of LH and human follicular fluid. Patches of monolayer consisting of fibroblasts form within 2 - 3 days of the culture of the fresh tissues.
- follicles After 1 week of culture, follicles separate out from the ovarian tissue, but remain attached to the monolayer. The maximal number of follicles separating out from the tissue appear about 1 week after initiating culture. After 40 days of culture in Costar dishes, a significant fraction of the ova reach a diameter of more than 80 ⁇ , of which about one-third are surrounded by the zona pellucida. Following induction of final maturation, extrusion of the first polar body is noted in ova grown in Costar dishes for 40 days. The mature ova may be collected and used directly for enucleation. Oocytes from mature human females. Human ova are obtained using the technique of Trotnow et al., Arch. Gynecol. 236: 211-7 (1985). A steering attachment is employed with the transducer of the Diasonics DS 1 sector scanner employing an aspiration needle gliding through a trocar, with continuous sonographic imaging of the aspiration needle. The patient is given epidural anaesthesia
- the oocytes may then be matured in vitro as follows.
- the immature oocytes are washed in TL-HEPES buffered medium containing 3 mg ml bovine serum bumin
- Fraction N The oocyte cumulus complexes are placed in TCM-199 containing 10% fetal calf serum, LH and/or FSH and estradiol at 39 °C. After about 20h in maturation medium, the oocytes are removed and placed in TL-HEPES with 1 mg/ml hyaluronidase and the cumulus cells are removed by repeated pipetting through a fine-bore pipet. The stripped oocytes are screened for polar bodies and those containing polar bodies (metaphase II oocytes) are selected for further use.
- Heifers are superovulated and artificially inseminated . Embryos are recovered from the reproductive tract on day 5 or 6 after standing estrus. The embryos are flushed from the reproductive tract with PBS and collected. In vitro matured, fertilized and cultured embryos are used as donor embryos on day 5 after fertilization. The fertilization process is described in Keefer et al., Mol. Reprod. Dev. 36: 469-74 (1993).
- Enucleation is performed using a beveled micropipette at approximately 18h post- initiation of maturation (hpm). Enucleation is confirmed in TL-HEPES medium plus bis- benzimide (Hoechst 33342, 3 ⁇ g/ml). Nuclear transfer
- NT unit bovine donor nucleus
- NT units are exposed for 4 min to ionomycin-6-DMAP (2mM) followed by 4 hrs in DMAP only (2mM) in TL-HEPES supplemented with lmg/ml serum albumin and then washed for 5min in TL-HEPES supplemented with 30mg/ml serum albumin.
- the NT units are then transferred into a microdrop of CRlaa culture media plus 10% FCS and 6mg/ml serum albumin in 4 well plates containing a confluent feeder layer of mouse embryonic fibroblasts.
- the NT units are cultured for 3 more days at 38.5 °C and 5% CO 2 .
- the culture medium is changed every 3 days until day 12 after the initiation of activation. At this time about 50 cells should be formed, which cells are mechanically removed from the zona and used to produce embryonic cell lines.
- mice embryonic fibroblasts Primary cultures of mouse embryonic fibroblasts are obtained from 14 - 16 day old murine fetuses. After the head, liver, heart and alimentary tract are aseptically removed, the embryos are minced and incubated for 30min at 37°C in prewarmed trypsin EDTA solution (0.05% try ⁇ sin/0.02% EDTA; GTBCO, Grand Island, NY). Fibroblast cells are plated in in tisssue culture flasks and cultured in alpha-MEM medium (BioWhittaker, Walkersville, MD) supplemented with 10% FCS, penicillin (lOORJ/ml) and streptomycin (50 ⁇ l/ml).
- alpha-MEM medium BioWhittaker, Walkersville, MD
- embryonic fibroblasts in 35 x 10 Nunc culture dishes (Baxter Scientific, McGaw Park, IL) are irradiated.
- the irradiated fibroblasts are grown and maintained in a humidified atmosphere with 5% CO 2 in air at 37 °C.
- Culture plates having a uniform monolayer of cells are used to culture embryonic cell lines. Production of embryonic cell lines:
- NT unit cells obtained as described above were washed and plated directly onto irradiated feeder fibroblast cells (see above). These cells included those of the inner portion of the NT unit.
- the cells are maintained in a growth medium consisting of alpha- MEM supplemented with 10% FCS and O.lmM ⁇ -mercaptoethanol. Growth medium is exchanged every 2 to 3 days. The initial colony is observed by the second or third day of culture. The colony is propagated and exhibits a similar morphology to previously disclosed mouse and bovine embryonic stem (ES) cells. Individual cells within the colony are not well defined and the perimeter of the colony is refractile and smooth in appearance. The cells have an epithelial appearance.
- ES mouse and bovine embryonic stem
- Chimeric NT units are selected and implanted in cows according to the following procedure: 1-5 NT units are implaned in the uterus. The resulting calves are grown to the appropriate stage for oocyte development, at which time the ova are aspirated and isolated. Alternatively, oocytes are obtained from adult females by superovulation and ultrasound- guided oocyte retrieval or from slaughtered cow ovaries.
- the chimeric ova obtained as described above are treated as described above for growth and enucleation, and are then ready to be used for receipt of a human nucleus.
- Human epithelial cells are lightly scraped from the inside of the mouth from a consenting human adult with a standard glass slide. The cells are washed off the slide into a Petri dish containing PBS with Ca or Mg. The cells are pipetted through a small-bore pipette to break up cell clumps into a single cell suspension. The cells are then transferred into a microdrop of TL-HEPES media containing 10% FCS under oil for nuclear transfer to enucleated chimeric bovine oocytes comprising human mitochondria using the procedure described above.
- the allochimeric cells may emplpy nuclei from substantially any convenient human cell source, such a fibroblasts, epithelial cells, keratinocytes, blood lymphocyte or bladder epithelial cell.
- the allochimeric cells are grown in culture and directed into various differentiation patterns, as described by Stice et al., (1998), supra, including preparation of myocytes.
- allochimeric human cells having a human nucleus and human mitochondria from different individuals. These cells find extensive use in that they provide a simulated natural human cell for studying cellular processes in the development of embryos and differentiation to differentiated cell types. The cells can also be used for producing differentiated cells for cell therapy or production of human factors.
- the subject cells provide cells which produce only human proteins, so as to be less likely to induce an immune response, permit genetic manipulation of the nucleus, to provide human cells which may be introduced into an individual who is the source of the nucleus, but where the nucleus is modified for therapeutic or other purposes, and provide a source of genotypically identical cells, which may be used for cloning of a particular genotype.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15206401A IL152064A0 (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogenic nucleus and mitochondria |
NZ521711A NZ521711A (en) | 2000-04-14 | 2001-04-16 | Modified oocytes and embryonic non-human stem cells able to be cultured into a variety of differentiated cell types |
AU2001257053A AU2001257053A1 (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogenic nucleus and mitochondria |
JP2001577429A JP2003530848A (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells containing allogeneic nuclei and mitochondria |
BR0110072-6A BR0110072A (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogeneic nucleus and mitochondria |
EP01930525A EP1282685A2 (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogenic nucleus and mitochondria |
CA002405555A CA2405555A1 (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogenic nucleus and mitochondria |
MXPA02010075A MXPA02010075A (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogenic nucleus and mitochondria. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19740700P | 2000-04-14 | 2000-04-14 | |
US60/197,407 | 2000-04-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001079445A2 true WO2001079445A2 (en) | 2001-10-25 |
WO2001079445A3 WO2001079445A3 (en) | 2002-07-11 |
Family
ID=22729292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/012265 WO2001079445A2 (en) | 2000-04-14 | 2001-04-16 | Pluripotent cells comprising allogenic nucleus and mitochondria |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1282685A2 (en) |
JP (1) | JP2003530848A (en) |
CN (2) | CN1427887A (en) |
AU (1) | AU2001257053A1 (en) |
BR (1) | BR0110072A (en) |
CA (1) | CA2405555A1 (en) |
IL (1) | IL152064A0 (en) |
MX (1) | MXPA02010075A (en) |
NZ (1) | NZ521711A (en) |
WO (1) | WO2001079445A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072708A2 (en) * | 2002-02-21 | 2003-09-04 | Advanced Cell Technology, Inc. | Pluripotent cells comprising allogenic nucleus and mitochondria |
US7030292B2 (en) | 2001-01-02 | 2006-04-18 | Stemron, Inc. | Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012242591B2 (en) * | 2011-04-14 | 2014-10-23 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
CN104830777A (en) * | 2014-02-28 | 2015-08-12 | 复旦大学 | Polar body genome reconstruction ovum, preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011197A (en) * | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
-
2001
- 2001-04-16 NZ NZ521711A patent/NZ521711A/en unknown
- 2001-04-16 CN CN01808875A patent/CN1427887A/en active Pending
- 2001-04-16 BR BR0110072-6A patent/BR0110072A/en not_active IP Right Cessation
- 2001-04-16 JP JP2001577429A patent/JP2003530848A/en active Pending
- 2001-04-16 CN CNA2005100527010A patent/CN1673361A/en active Pending
- 2001-04-16 MX MXPA02010075A patent/MXPA02010075A/en not_active Application Discontinuation
- 2001-04-16 AU AU2001257053A patent/AU2001257053A1/en not_active Abandoned
- 2001-04-16 CA CA002405555A patent/CA2405555A1/en not_active Abandoned
- 2001-04-16 WO PCT/US2001/012265 patent/WO2001079445A2/en active IP Right Grant
- 2001-04-16 IL IL15206401A patent/IL152064A0/en unknown
- 2001-04-16 EP EP01930525A patent/EP1282685A2/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011197A (en) * | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
Non-Patent Citations (3)
Title |
---|
EVANS M.J. ET AL.: 'Mitochondrial DNA genotypes in nuclear transfer-derived sheep' NATURE GENETICS vol. 23, September 1999, pages 90 - 93, XP002946451 * |
TAKEDA K. ET AL.: 'Dominant distribution of mitochondrial DNA from recipient oocytes in bovine embryos and offspring after nuclear transfer' JOURNAL OF REPRODUCTION AND FERTILITY vol. 116, 1999, pages 253 - 259, XP002946449 * |
WOLF D.P. ET AL.: 'Nuclear transfer in the rhesus monkey: Practical and basic implications' BIOLOGY OF REPRODUCTION vol. 60, 1999, pages 199 - 204, XP002946450 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030292B2 (en) | 2001-01-02 | 2006-04-18 | Stemron, Inc. | Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same |
WO2003072708A2 (en) * | 2002-02-21 | 2003-09-04 | Advanced Cell Technology, Inc. | Pluripotent cells comprising allogenic nucleus and mitochondria |
WO2003072708A3 (en) * | 2002-02-21 | 2004-02-05 | Advanced Cell Tech Inc | Pluripotent cells comprising allogenic nucleus and mitochondria |
Also Published As
Publication number | Publication date |
---|---|
CN1673361A (en) | 2005-09-28 |
MXPA02010075A (en) | 2003-02-12 |
CN1427887A (en) | 2003-07-02 |
CA2405555A1 (en) | 2001-10-25 |
BR0110072A (en) | 2004-07-06 |
EP1282685A2 (en) | 2003-02-12 |
AU2001257053A1 (en) | 2001-10-30 |
NZ521711A (en) | 2005-03-24 |
IL152064A0 (en) | 2003-05-29 |
WO2001079445A3 (en) | 2002-07-11 |
JP2003530848A (en) | 2003-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU742363B2 (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
AU740709B2 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplanta tion | |
US6215041B1 (en) | Cloning using donor nuclei from a non-quiesecent somatic cells | |
JP2001509362A (en) | Pig cloning using donor nuclei from differentiated cells | |
EP1017422A1 (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
JP2003509031A (en) | Cloning of pigs using nuclei from donor cells or differentiated cells and production of pluripotent pigs | |
WO2001079445A2 (en) | Pluripotent cells comprising allogenic nucleus and mitochondria | |
US20050095704A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
AU2007205775A1 (en) | Pluripotent cells comprising allogenic nucleus and mitochondria | |
WO2003072708A2 (en) | Pluripotent cells comprising allogenic nucleus and mitochondria | |
Stice | Cloning using donor nuclei from a non-quiesecent somatic cells | |
MXPA00000202A (en) | Cloning pigs using donor nuclei from differentiated cells | |
MXPA00000201A (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
MXPA99006464A (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
AU2011202964A1 (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
MXPA99001706A (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
AU2006202185A1 (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
AU2006236032A1 (en) | Nuclear transfer with differentiated fetal and adult donor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521711 Country of ref document: NZ Ref document number: 2001257053 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 152064 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2405555 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 577429 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010075 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018088759 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001930525 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001930525 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001930525 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 521711 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 521711 Country of ref document: NZ |